PRTK - Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Paratek Pharmaceuticals (PRTK) announces the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial ((NTM)) Pulmonary Disease caused by Mycobacterium abscessus complex (MABc). The U.S.-based study will enroll approx. 75 subjects, randomized in a 1.5 to 1 ratio.The primary study endpoints are improvement in symptoms and safety and tolerability following 12 weeks of treatment.Due to the small numbers of patients with this rare disease, Paratek expects the study will take about two years to complete enrollment.Paratek will host a conference call that will include a corporate update, key opinion leader update on NTM, and future development opportunities today, at 10:00 am ET.

For further details see:

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial